leadf
logo-loader
viewDestiny Pharma PLC
(
AIM:DEST
)

Destiny Pharma (LON:DEST) Elevator Pitch

Destiny Pharma is a clinical phase biotechnology company dedicated to the development of novel anti-infectives with a focus on infection prevention.

Destiny Pharma is a clinical phase biotechnology company dedicated to the development of novel anti-infectives with a focus on infection prevention.

The Company is developing novel antimicrobial drugs from its “in-house” XF platform and also from recently acquired Biotherapeutic products that harness beneficial components of the human microbiome. We have two exciting late stage clinical assets and a range of earlier research programmes.

XF-73 nasal is our novel Phase 2b clinical asset for the prevention of post-surgical Staphylococcal infections reporting data in Q1 2021. Our XF drug platform acts via an ultra-rapid action that kills targeted bacteria (including antibiotic resistant strains) leaving the bacteria unable to mount a resistance.

Destiny Pharma also recently acquired global rights to NTCD-M3 for the prevention of recurring Clostridioides difficile gut infections that is planned to start Phase 3 studies in 2022.

Destiny Pharma is also collaborating with SporeGen Limited on a novel treatment for the prevention of COVID-19 and similar respiratory viral infections using a Bacillus based approach. This project is at the preclinical development stage as are several earlier XF projects.

The Company will look to enter selected partnerships to develop it  assets and also apply for non-dilutive sources of grant and governmental funding, as it has done in the past, to assist in the development of its portfolio.

Quick facts: Destiny Pharma PLC

Follow
AIM:DEST

Price: 115.5 GBX

Market Cap: £69.14 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Market Report: FTSE hots up alongside British sun with markets near record...

FTSE100 made a healthy start as oil shares improved on crude rising to US$71 per barrel. London’s blue-chip index rose 25 to 7.105. The UK government has started talks with Oxford University and AstraZeneca (AZN.L) about a new version of thier COVID-19 vaccine that targets the South Africa...

on 06/02/2021

2 min read